Article

TLR7-agonist and antineoplastic MEK1/2-inhibitor combination unlocks interferon responses from macrophages

2019-04-22

Abstract excerpt

Type I interferons are a family of pleiotropic cytokines that exert anti-tumor actions directly on tumor cells and indirectly on the tumor immune microenvironment (TIME). Hitherto, therapeutic strategies aiming to garner the efficacies of interferon responses are still limited. Here we show a novel strategy that elicits an interferon signature response while targeting both tumor cells using antineoplastic mitogen-...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d1e2bb85-b202-5ed8-a03d-80f257953059
DOI: 10.1101/615609

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

TLR7-agonist and antineoplastic MEK1/2-inhibitor combination unlocks interferon responses from macrophagesDOI 10.1101/615609Read

PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockadeSemantic proximity Read

Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.Semantic proximity Read

Tumoral Interferon Beta Induces an Immune-Stimulatory Phenotype in Tumor-Associated Macrophages in Melanoma Brain Metastases.Semantic proximity Read

Interferon regulatory factors: A key to tumour immunitySemantic proximity Read

Signaling by Type I Interferons in Immune Cells: Disease ConsequencesSemantic proximity Read

Sustained interferon exposure creates a hyper-metastatic subset of melanoma cellsSemantic proximity Read

KSHV infection skews macrophage polarisation towards M2-like/TAM and activates Ire1 α-XBP1 axis up-regulating pro-tumorigenic cytokine release and PD-L1 expressionSemantic proximity Read

Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation.Semantic proximity Read

A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.Semantic proximity Read

Interferon α/β Enhances the Cytotoxic Response of MEK Inhibition in Melanoma.Semantic proximity Read

Differential TLR-ERK1/2 activity promotes viral ssRNA and dsRNA mimic-induced dysregulated immunity in macrophagesSemantic proximity Read

Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy-Paradoxical ERK Activation and Beyond.Semantic proximity Read